The Study
Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer.
This study gave two different treatments to two groups of people with advanced pancreatic cancer and saw which group lived longer. Because they randomly picked who got which treatment, we can say the new drug probably caused the longer life — not just that the two things happened together.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
Doctors tested a new pill called daraxonrasib on pancreatic cancer patients who had already tried other treatments. They compared it to standard chemotherapy.
Where does this study sit?
Systematic Reviews & Meta-analyses
Max 100Randomized Trials
Max 90Cohort Studies
Max 72Case-Control
Max 58Cross-Sectional
Max 44Case Reports & Series
Max 30Expert Opinion
Max 557 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. Considered the gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Doubling survival time and delaying cancer growth by more than double is a very big improvement for this aggressive cancer.
- 2Patients on the pill lived 13.2 months on average, compared to 6.6–6.7 months on chemo.
- 3Their cancer also took longer to grow back: 7.2–7.3 months vs.
- 43.5–3.6 months.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
The New England journal of medicine
Year
2026
Authors
E. O’Reilly, Z. Wainberg, A. Hendifar, M. Borad, F. Pietrantonio, Shubham Pant, P. Hammel, C. Cremolini, G. Manji, P. Oberstein, Ignacio Garrido-Laguna, C. Springfeld, Nilofer S. Azad, Makoto Ueno, S. Chui, Ying Zhang, Hina Patel, Yeonju Lee, Z. Salman, B. Wolpin
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.